bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to...
Pacira (PCRX) delivered earnings and revenue surprises of -11.67% and 2.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.